Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Reaffirms Their Buy Rating on CVS Health (CVS)

Tipranks - Tipranks - Thu Feb 12, 6:10AM CST

RBC Capital analyst Ben Hendrix reiterated a Buy rating on CVS Health yesterday and set a price target of $93.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Hendrix is a 4-star analyst with an average return of 5.2% and a 51.86% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, CVS Health, and The Ensign Group.

In addition to RBC Capital, CVS Health also received a Buy from TD Cowen’s Charles Rhyee in a report issued yesterday. However, today, TipRanks – Google reiterated a Hold rating on CVS Health (NYSE: CVS).

See today’s best-performing stocks on TipRanks >>

Based on CVS Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $102.87 billion and a GAAP net loss of $3.98 billion. In comparison, last year the company earned a revenue of $95.43 billion and had a net profit of $87 million

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).